I know most of you have read this but I did glean one small piece of info I was not totally sure on and that was Ovarian and Breast cancer assays will both be added to the Luminex platform I thought it would be Ovarian followed by Breast, IMO good news given the assays being transferred to Luminex [ the industry standard ] will IMO be a major de risking event and could signal early interest in the tests. If you wanted to stich a Bard deal up you would do it before the clinical studies were complete IMO as after Bard would have much more leverage. Anyway the upshot is IMO that there will be some very large companies very interested in the worlds first blood test that can tell the difference between benign and cancerous tumours and detect them early which is the key to survival rates. The clinical studies that will follow, with luck, will hopefully see as good or better results. Aimo DB
BD1 Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
